Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 3/20 | 0.47 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | DUT | P33316 | 1/20 | 0.31 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.31 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.31 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.31 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28406384 | 0.98 | CRBN (0.45) | CRBNDDB1PKMKDM4EGAA | |
| SCHEMBL21385228 | 0.69 | — | — | |
| SCHEMBL28426470 | 0.67 | CRBN (0.58) | CRBNDDB1PKML3MBTL1ALDH1A1 | |
| SCHEMBL23296154 | 0.65 | DDB1 (0.57) | CRBNDDB1KDM4EGAAALDH1A1 | |
| SCHEMBL23211167 | 0.64 | GRIA1 (0.47) | KDM4ELMNA | |
| SCHEMBL23296136 | 0.64 | DBH (0.54) | KDM4ESMN1; SMN2ALDH1A1LMNADUT | |
| SCHEMBL10423652 | 0.64 | — | — | |
| SCHEMBL8790967 | 0.64 | — | — | |
| SCHEMBL35355 | 0.64 | — | — | |
| SCHEMBL8377720 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2025-10-09 | — | — | US | disclosed |
| US-12336993-B2 | Therapeutic benefit of suboptimally administered chemical compounds | BROWN DENNIS M (US) | 2025-06-24 | — | — | US | disclosed |
| CN-118995720-B | Application of dsRNA in preventing and controlling cyantraniliprole-resistant bemisia tabaci | 青岛农业大学 | 2024-12-13 | — | — | CN | disclosed |
| CN-117695230-A | Stable-quality synergistic nicarbazin dry suspension and preparation method thereof | 浙江汇能生物股份有限公司 | 2024-03-15 | — | — | CN | disclosed |
| US-20230133044-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2023-05-04 | — | — | US | disclosed |
| US-11491154-B2 | Therapeutic benefit of suboptimally administered chemical compounds | BROWN DENNIS M (US) | 2022-11-08 | — | — | US | disclosed |
| CN-115124443-A | Nicarbazin metabolite hapten, artificial antigen, preparation method and application thereof | 华南农业大学 | 2022-09-30 | — | — | CN | disclosed |
| CN-103588661-A | Preparation of hapten and artificial antigen of nicarbazin | BEIJING WDWK BIOTECHNOLOGY CO LTD | 2014-02-19 | — | — | CN | disclosed |
| EP-1678181-B1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS INC (US) | 2008-12-31 | — | — | EP | disclosed |
| US-7449473-B2 | Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as A2b adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2008-11-11 | — | — | US | disclosed |
| EP-1678181-A2 | A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2006-07-12 | — | — | EP | disclosed |
| US-20050119287-A1 | A2B adenosine receptor antagonists | GILEAD PALO ALTO, INC. | 2005-06-02 | — | — | US | disclosed |
| WO-2005042534-A2 | A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133044-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | CRBN 2004/4885DDB1 278/4885PKM 4014/4885 |
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | CRBN 2004/4885DDB1 278/4885PKM 4014/4885 |
| US-11491154-B2 | Therapeutic benefit of suboptimally administered chemical compounds | UNG, DPYD, TPMT | CRBN 2004/4885DDB1 278/4885PKM 4014/4885 |
| US-20050119287-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA3 | CRBN 1162/4885DDB1 2473/4885PKM 4149/4885 |
| US-12336993-B2 | Therapeutic benefit of suboptimally administered chemical compounds | UNG, DPYD, TPMT | CRBN 2004/4885DDB1 278/4885PKM 4014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.